Research programme: microbiome-targeted therapeutics- Johnson & Johnson Innovative Medicine/Kaleido Biosciences
Latest Information Update: 28 Feb 2024
Price :
$50 *
At a glance
- Originator Kaleido Biosciences
- Developer Johnson & Johnson Innovative Medicine; Kaleido Biosciences
- Class Anti-infectives; Antiallergics
- Mechanism of Action Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hypersensitivity; Metabolic disorders
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for research development in Allergy(In children, In infants) in USA (PO)
- 28 Feb 2024 No recent reports of development identified for research development in Metabolic-disorders(In children, In infants) in USA (PO)
- 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)